Efficacy and safety of PD-1 inhibitors in combination with chemotherapy as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction cancer across subgroups: A comprehensive systematic review and meta-analysis
First-line treatment with PD-1 inhibitors combined with chemotherapy surpasses chemotherapy alone in efficacy for patients with HER2-negative advanced GC/GEJC, particularly in those with CPS ≥ 10 or high microsatellite instability, with tolerable adverse events.
Authors
- Xiaoli Ma (ORCID: https://orcid.org/0000-0001-7930-4944)
- Wen Yi (ORCID: https://orcid.org/0000-0002-4257-3355)
- Leiyu Cao
- Chengcheng Qu
- Wei Yu (ORCID: https://orcid.org/0000-0002-1777-5254)
- Li Zhang (ORCID: https://orcid.org/0000-0002-3475-7285)
- Yan Gao (ORCID: https://orcid.org/0000-0002-6541-8577)
- Muhetaibaier Hairoula
- Kalima Muhetaer
Institutions
- Xinjiang Medical University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1097/md.0000000000041751
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00